Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

TapImmune launches Phase II study of TPIV 200 to treat platinum-sensitive ovarian cancer

Go Top